Summary
Decrease of blood cells may be induced by either components of co-trimoxazole. Side effects of the trimethoprim component are much more frequent, particularly in risk groups. They are dose dependent, usually not severe, only rarely of clinical significance and easily treated or prevented by folate supplementation. In contrast, side effects of the sulfamethoxazole component seem to be extremely rare. They are similar to the hematological side effects of other sulfonamide drugs. They are idiosyncratic, nonpredictable and mostly mediated by the immune-system. They may be of life-threatening severity and no therapy is known except termination of exposure and supportive measures such as substitution of blood cells and antiinfectious therapy by non-related antibiotics.
Zusammenfassung
Beide Komponenten des Präparates „Co-trimoxazol“ können zu einer Veränderung des Blutbildes führen. Der Trimethoprim-Anteil verursacht jedoch wesentlich häufiger Zytopenien, insbesondere bei bestimmten Risikogruppen. Diese Nebenwirkungen sind dosisabhängig, gewöhnlich von leichter Form und daher nur selten von klinischer Bedeutung. Sie können durch Gabe von Fol-/Folinsäure verhindert bzw. behandelt werden. Demgegenüber sind Nebenwirkungen auf das Blutbild durch den Sulfamethoxazol-Anteil äußerst selten. Sie ähneln den bekannten Nebenwirkungen anderer Sulfonamidabkömmlinge. Diese Nebenwirkungen sind idiosynkratisch, nicht vorhersehbar und meistens immunmediiert. Es können Zytopenien von lebensbedrohendem Ausmaß auftreten, therapeutisch bleiben nur das sofortige Absetzen der Substanz sowie entsprechende supportive Maßnahmen wie z. B. Gabe von Blutkomponenten oder antibiotische Therapie mit nicht verwandten Pharmaka.
Similar content being viewed by others
Literature
Golde, D. W., Bersch, N., Quan, S. G. Trimethoprim and sulphamethoxazole inhibition of haematopoiesisin vitro. Br. J. Haematol. 40 (1978) 363–367.
Bjornson, B. H., McIntyre, A. P., Harvey, J. M., Tauber, A. I. Studies on the effect of trimethoprim and sulfamethoxazole on human granulopoesis. Amer. J. Haematol. 23 (1986) 1–7.
Bow, E. J., Louie, T. J., Riben, P. D., McNaughton, R. D., Harding, G. K. M., Ronald, A. R. Randomized controlled trial comparing trimethoprim/sulfamethoxazole and trimethoprim for infection prophylaxis in hospitalized granulocytopenic patients. Am. J. Med. 76 (1984) 223–233.
Sive, J., Green, R., Metz, J. Effect of trimethoprim on folate dependent DNA-synthesis in human bone marrow. J. Clin. Pathol. 25 (1972) 194.
Jewkes, R. F., Edwards, M. S., Grant, B. J. B. Haematological changes in a patient on long-term treatment with a trimethoprimsulphonamide combination. Postgrad. Med. J. 46 (1970) 723–726.
Kahn, S. B., Fein, S. A., Brodsky, I. Effects of trimethoprim on folate metabolism in man. Clin. Pharmakol. Ther. 9 (1969) 550–560.
Scott, J. M., Weir, D. G. Drug induced megaloblastic change. Clin. Haematol. 9 (1980) 587–606.
Stebbins, R., Bertino, J. R. Megaloblastic anemia produced by drugs. Clin. Haematol. 5 (1976) 619.
Chanarin, J., England, J. M. Toxicity of trimethoprim-sulphamethoxazole in patients with megaloblastic haemopoiesis. Br. Med. J. I (1972) 651–653.
Rooney, P. J., Housley, E. Trimethoprim-sulfamethoxazole in folic acid deficiency. Br. Med. J. 2 (1972) 656.
Dekker, A. W., Rozenberg Arska, M., Sixma, J. J. Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukaemia. Ann. Intern. Med. 95 (1981) 555–559.
Wade, J. C., de Jongh, C. A., Newman, K. A. Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: trimethoprim-sulfamethoxazole vs. nalidixic acid. J. Infect. Dis. 147 (1983) 624–634.
Andsell, V. E., Wright, S. G., Hutchinson, D. B. Megaloblastic anemia associated with combined pyrimethamine and cotrimoxazole administration. Lancet II (1976) 1257.
Fleming, A. F., Warrell, D. A., Dickmeiss, H. Co-trimoxazole and the blood. Lancet II (1974) 284.
Gordin, F. M., Simon, G. L., Wofsy, C. B., Mills, J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 100 (1984) 495–499.
Kovacs, J. A., Hiemenz, J. W., Macher, A. M. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immune deficiencies. Ann. Intern. Med. 100 (1984) 663.
Deeg, H. J., Meyers, J. D., Storb, R., Graham, T. C., Weiden, P. L. Effect of trimethoprim-sulfamethoxazole on hematological recovery after total body irradiation and autologous marrow infusion in dogs. Transplantation 28 (1979) 243–246.
Principi, N., Marchisio, P., Biasini, A., Dalla Villa, A., Biasini, G. Early and late neutropenia in children treated with co-trimoxazole (trimethoprim-sulfamethoxazole). Acta Paediatr. Scand. 73 (1984) 763–767.
Rubin, R. H., Swartz, M. N. Trimethoprim-sulfamethoxazole. N. Engl. J. Med. 303 (1980) 426–432.
Swanson, M., Cook, R. Sulfonamides. Drugs, chemicals and blood dyscrasias. Drug Intelligence Publications, Hamilton/Ill. 1977, pp. 1013–1016.
Havas, L., Fernex, M., Lenox-Smith, I. The clinical efficacy and tolerance of co-trimoxazole (Bactrim; Septrin). An analysis of 37,340 cases. Clinical Trails J. 10 (1973) 81–86.
Swanson, M., Cook, R. Trimethoprim-sulfamethoxazole. Drugs, chemicals and blood dyscrasias. Drug Intelligence Publications, Hamilton/Ill. 1977, pp. 1069–1076.
Baumgartner, A., Hoign, R., Müller, U., Hess, T. Medikamentöse Schäden des Blutbildes. Schweiz. Med. Wochenschr. 112 (1982) 1530–1539.
Tamtamy, S. E. Co-trimoxazole and the blood. Lancet II (1974) 929–930.
Poskitt, E. M. E., Parkin, J. M. Effect of trimethoprim-sulphamethoxazole combination on folate metabolism in malnourished children. Arch. Dis. Child. 47 (1972) 626–630.
Lacey, R. W., Hawkey, P. M., Devaraj, S. K., Millar, M. R., Inglis, T. Y., Godwin, P. G. R. Co-trimoxazole toxicity. Br. Med. J. 1 (1985) 691–698.
Böttiger, L. E., Westerholm, B. Drug-induced blood dyscrasias in Sweden. Br. Med. J. 2 (1973) 339–343.
Asmar, B. I., Magboll, S., Dajani, A. S. Hematologic abnormalities after trimethoprim-sulfamethoxazole therapy in children. Amer. J. Dis. Child. 135 (1974) 110–113.
Hoign, R. Sulfonamides, antibacterial and antiviral drugs. Mylers side effects of drugs. 10th Edition. Chapter 30. Elsevier, Amsterdam, New York, Oxford 1984, pp. 545–555.
Inman, W. H. W. Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone. Br. Med. J. 1 (1977) 1500–1505.
Jick, S. S., Jick, H., Habakangas, J. A. S., Dinan, B. J. Co-trimoxazole toxicity in children. Lancet II (1984) 723–726.
Kurrle, E., Bhaduri, S., Krieger, D., Pflieger, H., Heimpel, H. Antimicrobial prophylaxis in acute leukaemia: prospective randomized study comparing two methods of selective decontamination. Klin. Wochenschr. 61 (1983) 691–698.
Arneborn, P., Palmblad, J. Drug-induced neutropenia — a survey for Stockholm 1973–1978. Acta Med. Scand. 212 (1982) 289–292.
Kiefel, V., Santoso, S., Schmidt, S., Salama, A., Mueller-Eckhardt, C. Metabolic-specific (IgG) and drug-specific antibiodies (IgG, IgM) in two cases of trimethoprim-sulfamethoxazole induced immune thrombocytopenia. Transfusion 27 (1987) 513.
Danielson, D. A., Douglas III, S. W., Herzog, P., Jick, H., Porter, J. B. Drug-induced blood disorders. JAMA 252 (1984) 3257–3260.
Tschan, M., Neuhaus, K. Knochenmarksschädigung durch Medikamente: Abklärung, therapeutische und prophylaktische Maßnahmen. Schweiz. Rundschau Med. 67 (1978) 1124–1128.
Böttiger, L. E., Böttiger, B. Incidence and cause of aplastic anemia, hemolytic anemia, agranulocytosis and thrombocytopenia. Acta Med. Scand. 210 (1981) 475–479.
Böttiger, L. E., Westerholm, B. Thrombocytopenia I. Incidence and etiology. Acta Med. Scand. 191 (1972) 535–540.
Dickson, H. G. Trimethoprim-sulfamethoxazole and thrombocytopenia. Med. J. Austr. 2 (1978) 5–7.
Claas, F. H. J., Van de Meen, J. W. M., Langerak, J. Immunological effect of co-trimoxazole on platelets. Br. Med. J. 2 (1979) 898.
Kelton, J. G., Meltzer, D., Moore, J., Giles, A. R., Wilson, W. E., Barr, R., Hirsh, J., Neame, P. B., Powers, P. J., Walker, I., Bianchi, F., Carter, C. J. Drug-induced thrombocytopenia is associated with increased binding of IgG to platelets bothin vivo andin vitro. Blood 58 (1981) 524–529.
Miescher, P. A., Graf, J. Drug-induced thrombocytopenia. Clin. Haematol. 9 (1980) 505–519.
Committee on Safety of Medicines (1985) unpublished report.
Böse, W., Karama, A., Linzenmeier, G., Olbing, H., Wellmann, P. Controlled trial of co-trimoxazole in children with urinary-tract infection. Lancet II (1974) 614–616.
Heimpel, H., Heit, W. Drug-induced aplastic anaemia: clinical aspects. Clin. Haematol. 9 (1980) 641–662.
Lennon, D. Co-trimoxazole toxicity. Lancet II (1984) 1152.
Anonymous: Serious adverse drug reactions with sulfonamides. FDA Drug Bull. 14 (1984) 5.
Stockley, I. H. Drug Interactions. Blackwell Scientific Publications, Oxford 1978.
Idänpän-Heikkilä, J., Tuomisto, J. Miscellaneous antibacterial and antiviral drugs. Side effects of drugs annual 10th edition Chapter 30. Elsevier, Amsterdam, New York, Oxford 1986, pp. 261–268.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Heimpel, H., Raghavachar, A. Hematological side effects of co-trimoxazole. Infection 15 (Suppl 5), S248–S253 (1987). https://doi.org/10.1007/BF01643198
Issue Date:
DOI: https://doi.org/10.1007/BF01643198